A sensitive and selective liquid chromatography-tandem mass spectrometry method for the simultaneous quantification of actinomycin-D and vincristine in children with cancer

Journal of Mass Spectrometry

Volumn 42, Issue 6, 2007, Pages 761-770

  Lee, James I ^a   Skolnik, Jeffrey M ^a   Barrett, Jeffrey S ^a   Adamson, Peter C ^a  

^a CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

Author keywords

Actinomycin D; Cancer; LC MS MS; Pediatric; Vincristine

Indexed keywords

LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; ONCOLOGY; PHARMACOKINETICS; QUALITY CONTROL;

ACTINOMYCIN-D; PEDIATRIC TRIALS; VINCRISTINE;

PROTEINS;

DACTINOMYCIN; VINCRISTINE;

ACCURACY; AREA UNDER THE CURVE; ARTICLE; CANCER; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG STABILITY; DRUG STORAGE; HUMAN; LIQUID CHROMATOGRAPHY; PRIORITY JOURNAL; QUALITY CONTROL; QUANTITATIVE ANALYSIS; SENSITIVITY ANALYSIS; TANDEM MASS SPECTROMETRY;

ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHILD; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DACTINOMYCIN; HUMANS; REPRODUCIBILITY OF RESULTS; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; TANDEM MASS SPECTROMETRY; VINCRISTINE;

EID: 34250827921     PISSN: 10765174     EISSN: 10969888     Source Type: Journal    
DOI: 10.1002/jms.1211     Document Type: Article

References (18)

1. Davidson A, Pritchard J. Actinomycin D, hepatic toxicity and . Wilms' tumour - a mystery explained? European Journal of Cancer 1998; 34: 1145.
2. Flamant F, Rodary C, Rey A, Praquin MT, Sommelet D, Quintana E, Theobald S, Brunat-Mentigny M, Otten J, Voute PA, Habrand JL, Martelli H, Barrett A, Terrier-Lacombe MJ, Oberlin O. Treatment of non-metastatic rhabdomyosarcomas in childhood and adolescence. Results of the second study of the International Society of Paediatric Oncology: MMT84. European Journal of Cancer 1998; 34: 1050.
3. Frei E III. The clinical use of actinomycin. Cancer Chemotherapy Reports 1974; 58: 49.
4. Rahmani R, Zhou XJ. Pharmacokinetics and metabolism of vinca alkaloids. Cancer Surveys 1993; 17: 269.
5. Van den Berg HW, Desai ZR, Wilson R, Kennedy G, Bridges JM, Shanks RG. The pharmacokinetics of vincristine in man: reduced drug clearance associated with raised serum alkaline phosphatase and dose-limited elimination. Cancer Chemotherapy and Pharmacology 1982; 8: 215.
6. Veal GJ, Errington J, Sludden J, Griffin MJ, Price L, Parry A, Hale J, Pearson AD, Boddy AV. Determination of anti-cancer drug actinomycin D in human plasma by liquid chromatography-mass spectrometry. Journal of Chromatography B, Analytical Technologies in the Biomedical and Life Sciences 2003; 795: 237.
7. Green DM, Finklestein JZ, Norkool P, D'Angio GJ. Severe hepatic toxicity after treatment with single-dose dactinomycin and vincristine. A report of the National Wilms' Tumor Study. Cancer 1988; 62: 270.
8. Green DM, Norkool P, Breslow NE, Finklestein JZ, D'Angio GJ. Severe hepatic toxicity after treatment with vincristine and dactinomycin using single-dose or divided-dose schedules: a report from the National Wilms' Tumor Study. Journal of Clinical Oncology 1990; 8: 1525.
9. Kanwar VS, Albuquerque ML, Ribeiro RC, Kauffman WM, Furman WL. Veno-occlusive disease of the liver after chemotherapy for rhabdomyosarcoma: case report with a review of the literature. Medical and Pediatric Oncology 1995; 24: 334.
10. Skolnik JM, Barrett JS, Shi H, Adamson PC. A liquid chromatography-tandem mass spectrometry method for the simultaneous quantification of actinomycin-D and vincristine in children with cancer. Cancer Chemotherapy and Pharmacology 2006; 57: 458.
11. Schmidt MS, Huang R, Classon RJ, Murry DJ. Determination of vincristine in infant plasma by liquid chromatography-atmospheric pressure chemical ionization-mass spectroscopy. Journal of Pharmaceutical and Biomedical Analysis 2006; 41: 540.
12. United States Health and Human Services. Guidance for industry: bioanalytical method validation. 2001; http:// www.fda.gov/cder/guidance/index. htm#Biopharmaceutics.
13. Taylor PJ. Matrix effects: the Achilles heel of quantitative high-performance liquid chromatography-electrospray-tandem mass spectrometry. Clinical Biochemistry 2005; 38: 328.
14. Matuszewski BK, Constanzer ML, Chavez-Eng CM. Matrix effect in quantitative LC/MS/MS analyses of biological fluids: a method for determination of finasteride in human plasma at picogram per milliliter concentrations. Analytical Chemistry 1998; 70: 882.
15. Matuszewski BK, Constanzer ML, Chavez-Eng CM. Strategies for the assessment of matrix effect in quantitative bioanalytical methods based on HPLC-MS/MS. Analytical Chemistry 2003; 75: 3019.
16. Dams R, Huestis MA, Lambert WE, Murphy CM. Matrix effect in bio-analysis of illicit drugs with LC-MS/MS: influence of ionization type, sample preparation, and biofluid. Journal of the American Society for Mass Spectrometry 2003; 14: 1290.
17. Veal GJ, Cole M, Errington J, Parry A, Hale J, Pearson AD, Howe K, Chisholm JC, Beane C, Brennan B, Waters F, Glaser A, Hemsworth S, McDowell H, Wright Y, Pritchard-Jones K, Pinkerton R, Jenner G, Nicholson J, Elsworth AM, Boddy AV. Pharmacokinetics of dactinomycin in a pediatric patient population: a United Kingdom Children's Cancer Study Group Study. Clinical Cancer Research 2005; 11: 5893.
18. Bender RA, Castle MC, Margileth DA, Oliverio VT. The pharmacokinetics of [3H]-vincristine in man. Clinical Pharmacology and Therapeutics 1977; 22: 430.